Literature DB >> 8723496

Kill kinetics and regrowth patterns of Pseudomonas aeruginosa exposed to concentration-time profiles of tobramycin simulating in vivo infusion and bolus dosing.

P J Wood1, L L Ioannides-Demos, E B Bastone, W J Spicer, A J McLean.   

Abstract

Pseudomonas aeruginosa ATCC 27853 was exposed to tobramycin concentration-time profiles modelling in vivo bolus and infusion dosing. Dependence of bactericidal and bacteriostatic activity on the initial profile of peak concentration (bolus effect > infusion) and area under the antibiotic concentration-time curve was observed at peak concentration/MIC ratios of 10 or below.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8723496      PMCID： PMC163321          DOI： 10.1128/AAC.40.5.1321

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Safety of the bolus administration of gentamicin.

Authors:  J Mendelson; J Portnoy; V Dick; M Black
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

2.  Once-daily dosing decreases renal accumulation of gentamicin and netilmicin.

Authors:  G A Verpooten; R A Giuliano; L Verbist; G Eestermans; M E De Broe
Journal:  Clin Pharmacol Ther       Date:  1989-01       Impact factor: 6.875

Review 3.  Pharmacokinetics of aminoglycoside antibiotics in blood, inner-ear fluids and tissues and their relationship to ototoxicity.

Authors:  C M Henley; J Schacht
Journal:  Audiology       Date:  1988

4.  Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features.

Authors:  P Tran Ba Huy; D Deffrennes
Journal:  Acta Otolaryngol       Date:  1988 May-Jun       Impact factor: 1.494

Review 5.  Pulse dosing versus continuous infusion of antibiotics. Pharmacokinetic-pharmacodynamic considerations.

Authors:  M LeBel; M Spino
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

6.  Absence of toxicity in patients with malignant otitis externa following long-term treatment with high dosage tobramycin.

Authors:  L L Ioannides-Demos; S C Li; E B Bastone; D W Spelman; R E Hooper; V C Cousins; A J McLean
Journal:  J Antimicrob Chemother       Date:  1994-08       Impact factor: 5.790

7.  Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs.

Authors:  P Tran Ba Huy; P Bernard; J Schacht
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

8.  Kinetics of antimicrobial activity.

Authors:  B Vogelman; W A Craig
Journal:  J Pediatr       Date:  1986-05       Impact factor: 4.406

9.  Aminoglycoside binding sites in the inner ears of guinea pigs.

Authors:  P Tran Ba Huy; D Deffrennes
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

10.  Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia.

Authors:  J E Kapusnik; C J Hackbarth; H F Chambers; T Carpenter; M A Sande
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226
View more
  2 in total

1.  Initial concentration-time profile of gentamicin determines efficacy against Enterobacter cloacae ATCC 13047.

Authors:  C R Rayner; L L Ioannides-Demos; J A Brien; L L Liolios; W J Spicer
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

2.  Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure.

Authors:  L L Ioannides-Demos; L Liolios; P Wood; W J Spicer; A J McLean
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.